The Drug Enforcement Agency received a recommendation to reclassify cannabis as a Schedule III drug, a move that would be a boon to research and patient care.

On Oct. 24, legislators, health law experts and others will dicsuss the current state of telehealth policy at the Arizona Telemedicine Program’s annual summit.

Problems with edible cannabis products in Arizona spiked in 2020 during the pandemic and have stayed at a heightened number since voters legalized recreational marijuana that year.

Arizona health officials this week scaled back the state's COVID-19 dashboard and declared the disease "a common respiratory illness."

A new study found that reactions such as chills, fatigue, headache and malaise that can follow vaccination may be signs of a vigorous immune response.

Presenting at the Alzheimer’s Research and Prevention Foundation’s annual conference in Phoenix, Roberta Diaz Brinton, PhD, director of the UArizona Center for Innovation in Brain Science, cited chronic conditions that could lead to Alzheimer's disease.

A new study led by researchers in the Mel and Enid Zuckerman College of Public Health, published in the journal Vaccine, identified why less than 20% of the eligible population received COVID-19 boosters in 2022.

Researchers with the ongoing Arizona CoVHORT research study at the Zuckerman College of Public Health were awarded $3.2 million by the National Institute of Diabetes and Digestive and Kidney Diseases for a study of gastrointestinal symptoms, specifically irritable bowel syndrome, as a condition of long COVID.

Phillip Kuo, MD, PhD, FACR, professor of medical imaging at the College of Medicine – Tucson, is interviewed about his research on the prostate cancer drug flotufolastat F 18, which was presented at the American Society for Radiation Oncology annual meeting in San Diego, California.